Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,188 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer
Interventions
ETBX-021
Biological
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
El Segundo, California • Sioux Falls, South Dakota
Conditions
Breast Cancer
Interventions
Trastuzumab
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Conditions
Breast Cancer
Interventions
letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
172
States / cities
Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more
Not listed No phase listed Observational

NSABP Biospecimen Discovery Project

NCT01850628
Conditions
Breast Cancer
Interventions
Paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more
Conditions
Metastatic Breast Cancer
Interventions
biomarker study
Other
Lead sponsor
Side-Out Foundation
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Trastuzumab Emtansine
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, conventional surgery, neoadjuvant therapy
Biological · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Solid Tumors, Breast Cancer
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • New York, New York
Conditions
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
38
States / cities
Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

NCT02547987
Conditions
Breast Cancer
Interventions
Docetaxel, Carboplatin
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
142
States / cities
Birmingham, Alabama • Mobile, Alabama • Sedona, Arizona + 128 more
Conditions
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Cohort 1 neo-adjuvant, Cohort 2 neo-adjuvant, Cohort 1 adjuvant, Cohort 2 adjuvant
Drug
Lead sponsor
William Sikov MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Providence, Rhode Island
Conditions
Breast Cancer, Brain Metastasis, Brain Cancer
Interventions
T-DM1, TMZ
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Herceptin, Navelbine, Doxorubicin, Cyclophosphamide, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Abemaciclib, Fulvestrant, Aromatase Inhibitors
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Houston, Texas
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Conditions
Breast Cancer
Interventions
chart abstraction
Other
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Marquette, Michigan • Henderson, North Carolina • West Columbia, South Carolina + 1 more
Conditions
Breast Cancer
Interventions
89Zr-Trastuzumab Human Dosimetry and Safety, HER2 Positive Lesion Detection and Safety
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Breast Cancer, DCIS
Interventions
HER-2 Pulsed Dendritic cell Vaccine
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more